Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Lupe G Salazar"'
Autor:
Mary L Disis, John B Liao, Jessica L Reichow, Lupe G Salazar, Sasha E Stanton, Katie M Hitchcock-Bernhardt, James Y Dai, Jong-Baeck Lim, Theodore A Gooley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 11 (2024)
Background For best efficacy, vaccines must provide long-lasting immunity. To measure longevity, memory from B and T cells are surrogate endpoints for vaccine efficacy. When antibodies are insufficient for protection, the immune response must rely on
Externí odkaz:
https://doaj.org/article/d9885f5707074dfbaef34741c99d4138
Autor:
Mary L. Disis, Yushe Dang, Andrew L. Coveler, Jennifer S. Childs, Doreen M. Higgins, Ying Liu, Jing Zhou, Sean Mackay, Lupe G. Salazar
Publikováno v:
Clinical Cancer Research. :OF1-OF10
Purpose: High levels of type I T cells are needed for tumor eradication. We evaluated whether the HER2-specific vaccine–primed T cells are readily expanded ex vivo to achieve levels needed for therapeutic infusion. Patients and Methods: Phase I/II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e05a48e2d7762599bcb9201063e71427
https://doi.org/10.1158/1078-0432.ccr-22-3578
https://doi.org/10.1158/1078-0432.ccr-22-3578
Autor:
Lupe G. Salazar, Sean Mackay, Jing Zhou, Ying Liu, Doreen M. Higgins, Jennifer S. Childs, Andrew L. Coveler, Yushe Dang, Mary L. Disis
Flow chart of participants.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::303b86c44495461d46e57265526d3563
https://doi.org/10.1158/1078-0432.22802188.v1
https://doi.org/10.1158/1078-0432.22802188.v1
Autor:
Lupe G. Salazar, Sean Mackay, Jing Zhou, Ying Liu, Doreen M. Higgins, Jennifer S. Childs, Andrew L. Coveler, Yushe Dang, Mary L. Disis
Detailed adverse events.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::100382b238e59f5964e5586c055adc3d
https://doi.org/10.1158/1078-0432.22802179
https://doi.org/10.1158/1078-0432.22802179
Autor:
Lupe G. Salazar, Sean Mackay, Jing Zhou, Ying Liu, Doreen M. Higgins, Jennifer S. Childs, Andrew L. Coveler, Yushe Dang, Mary L. Disis
Purpose:High levels of type I T cells are needed for tumor eradication. We evaluated whether the HER2-specific vaccine–primed T cells are readily expanded ex vivo to achieve levels needed for therapeutic infusion.Patients and Methods:Phase I/II non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e012bc0e2d1134d2773e9c3db0e593e
https://doi.org/10.1158/1078-0432.c.6641713
https://doi.org/10.1158/1078-0432.c.6641713
Autor:
David A. Riseberg, Timothy J. Pluard, Shakeela W Bahadur, Lupe G. Salazar, Hope S. Rugo, Seock-Ah Im, William J. Gradishar, Shengyan Hong, Young-Hyuck Im, Trevor M Feinstein, Miguel Henriques Abreu, Antonino Musolino, Edwin P. Rock, Viorela Pop, Fatima Cardoso, Mark D. Pegram, Rossana Berardi, Yelena Novik, Javier Cortes, Giuseppe Curigliano, Serafin Morales Murillo, Kenneth Jacobs, Alfredo Falcone
Publikováno v:
Cancer Research. 81:PS10-24
Background: Margetuximab (M) is an investigational Fc-engineered, anti-HER2 monoclonal antibody with the same epitope specificity as trastuzumab (T). Relative to T, Fc engineering of M increases binding affinity for the activating Fc receptor (FcR) C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca44da885a57e29a600f1ae9727193d2
https://doi.org/10.1158/1538-7445.sabcs20-ps10-24
https://doi.org/10.1158/1538-7445.sabcs20-ps10-24
Autor:
Mary L. (Nora) Disis, Katherine A. Guthrie, Ying Liu, Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, Yushe Dang, Lupe G. Salazar
Publikováno v:
JAMA Oncology. 9:71
ImportanceHigh levels of ERBB2 (formerly HER2)–specific type 1 T cells in the peripheral blood are associated with favorable clinical outcomes after trastuzumab therapy; however, only a minority of patients develop measurable ERBB2 immunity after t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::337e5551a6765204a8daa5d035e98043
https://doi.org/10.1001/jamaoncol.2022.5143
https://doi.org/10.1001/jamaoncol.2022.5143
Autor:
Jennifer M. Specht, Lupe G. Salazar, Hannah M. Linden, BJ Buening, AJ Liu, Pavani Chalasani, M Peha, Vijayakrishna K. Gadi, JA Khanjian
Publikováno v:
Cancer Research. 79:P1-14
Background: Eribulin mesylate is a non-taxane microtubule dynamics inhibitor approved by FDA in treatment of metastatic breast cancer (MBC) based on improvements in overall survival in the pivotal EMBRACE trial. Eribulin is approved at 1.4mg/m2 admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61a3b07e55e5ffb418e609725d88f557
https://doi.org/10.1158/1538-7445.sabcs18-p1-14-02
https://doi.org/10.1158/1538-7445.sabcs18-p1-14-02
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1738-1742
There is no preferred treatment option for metastatic breast cancer; therefore, treatment should provide palliation, prolong survival, control symptoms, and improve quality of life. Liposomal doxorubicin formulations have been shown to have less alop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c297e2350454598c5c1b7c4c83c95f5
https://doi.org/10.1177/1078155218798157
https://doi.org/10.1177/1078155218798157
Autor:
William J. Gradishar, Francesco Ricci, Shengyan Hong, Antonino Musolino, Gail S. Wright, Javier Cortes, Sutton Edlich, Timothy J. Pluard, Seock-Ah Im, Thomas Bachelot, Peter A. Kaufman, Fatima Cardoso, Mark D. Pegram, Edwin P. Rock, Giuseppe Curigliano, Michelino De Laurentiis, Lupe G. Salazar, Denise A. Yardley, Hope S. Rugo
Publikováno v:
Cancer Research. 80:GS1-02
Background: Human epidermal growth factor receptor 2 (HER2)-targeting monoclonal antibodies (mAb) are the standard of care in early-to-advanced HER2+ breast cancer. However, for relapsed/refractory disease, limited options exist after progression on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86578312e2f9647b8e1285517e9535d5
https://doi.org/10.1158/1538-7445.sabcs19-gs1-02
https://doi.org/10.1158/1538-7445.sabcs19-gs1-02